Here are three key themes to pay close attention to ahead of Thursday night's tech earnings deluge.
Rather than use the money for hiring and capital purchases, companies plowed the cash into buybacks and dividends.
PENNSAUKEN, N.J. _ J&J Snack Foods Corp. on Monday reported fiscal second-quarter profit of $16 million. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 89 cents per share. J&J Snack Foods shares have risen 2 percent since the beginning of the year.
You might think market risks are declining, but pay close attention to these four themes.
LONDON— Britain has reclaimed its place as one of the top five countries that firms look to make deals in, just six months after dropping off the list in the wake of the country's surprise to leave the European Union, according to a survey released Monday. In its half-yearly report of business executives, consulting firm EY said Britain has rebounded to be the third...
Samsung Bioepis has won regulatory approval for key biosimilar drug, the first time the company's product has been approved for U.S. use.
South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade.
The U.S. Food and Drug Administration approved Renflexis, developed by Samsung Bioepis Co. of South Korea. Its U.S. partner, Merck& Co. of Kenilworth, New Jersey, will market Renflexis. The first biosimilar for Remicade, Inflectra from New York- based Pfizer Inc., went on sale in November at a 15 percent discount.
Alphabet's Verily is working with Duke and Stanford to enroll 10,000 people to help it create a map of human health.
Investors are selling big dividend payers as bond yields rise, and a sharp drop in IBM sent the Dow Jones industrial average down. The Dow lost 114 points, or 0.6 percent, to 20,409. Half of the blue-chip index's losses came from IBM. The Russell 2000 index of small-company stocks added 7 points, or 0.5 percent, to 1,368 after a late gain a day earlier.
Cardinal Health Inc., down $9.44 to $72.39. Goldman Sachs Group Inc., down $10.67 to $215.59. Johnson& Johnson, down $3.90 to $121.82.
The Dow dropped about 110 points and the S&P and Nasdaq both fell slightly.
U.S. stocks fell Tuesday after weak first-quarter reports from Johnson& Johnson and Goldman Sachs frustrated investors who hope that company earnings are on the rise. Health care companies declined the most. The Russell 2000 index of small-company stocks added 0.71 points, or 0.1 percent, to 1,361.89.
Shares of Actelion buyer Johnson & Johnson fell 3.6 percent to $121.11 in the biggest one-day percentage decline in eight years.
Cardinal Health says it expects earnings at the lower end of its forecast, causing a 12 percent tumble in shares.
NEW YORK— U.S. stocks fell Tuesday after weak first-quarter reports from Johnson& Johnson and Goldman Sachs frustrated investors who hope that company earnings are on the rise. Johnson& Johnson took its biggest one-day loss in a year. Kate Warne, an investment strategist for Edward Jones, said Goldman Sachs and Johnson& Johnson had a dramatic effect on stocks...
Stocks are closing lower on Wall Street as poor results from Johnson& Johnson, Goldman Sachs and other companies put a damper on buying. Johnson& Johnson lost 3.1 percent Tuesday and drug distributor Cardinal Health slumped 11.5 percent. Health care stocks and banks are leading U.S. indexes broadly lower in midday trading on Wall Street.
U.S. stock index futures pointed to a lower open on Tuesday morning as traders eyed escalating geopolitical tensions concerning North Korea.
Some of the names on the move ahead of the open.
Increased pressure to cut medicine prices and an industry-wide slowdown in consumer health product sales is hurting health care giant Johnson& Johnson. The world's biggest maker of health care products cited its pending $30 billion purchase of biopharmaceutical company Actelion for the raised forecast. The New Brunswick, New Jersey- based company on...